Benitec Biopharma Files 8-K Report

Ticker: BNTC · Form: 8-K · Filed: Jul 9, 2025 · CIK: 1808898

Benitec Biopharma INC. 8-K Filing Summary
FieldDetail
CompanyBenitec Biopharma INC. (BNTC)
Form Type8-K
Filed DateJul 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, financial-exhibits

TL;DR

Benitec Biopharma filed an 8-K, mostly standard disclosures and exhibits. Watch for details.

AI Summary

On July 9, 2025, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Benitec Biopharma is making a regulatory disclosure and submitting financial exhibits, which is standard for public companies but may contain details about their financial health or operational updates.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.

Key Players & Entities

FAQ

What specific financial statements or exhibits are included in this 8-K filing?

The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details are not provided in the excerpt.

What is the primary purpose of this 8-K filing for Benitec Biopharma Inc. on July 9, 2025?

The filing serves as a Current Report, primarily for Regulation FD Disclosure and to submit Financial Statements and Exhibits.

Where are Benitec Biopharma Inc.'s principal executive offices located?

Benitec Biopharma Inc.'s principal executive offices are located at 3940 Trust Way, Hayward, California 94545.

What is Benitec Biopharma Inc.'s Commission File Number?

Benitec Biopharma Inc.'s Commission File Number is 001-39267.

Is this filing related to any specific event or update beyond standard disclosures?

The excerpt mentions 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as the items of disclosure, suggesting standard reporting rather than a specific, singular material event detailed in this portion.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 9, 2025 regarding Benitec Biopharma Inc. (BNTC).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing